ArticleAnnals of surgical oncology2026
The Role of Surgery on the Treatment of Primary Pulmonary Sarcomas and Pulmonary Sarcomatoid Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveWe aimed to investigate clinicopathological features and survival outcomes of patients diagnosed with primary pulmonary sarcoma (PPS) or pulmonary sarcomatoid carcinoma (PSC).
methodsBoth PPS (N = 156) and PSC (N = 175) patients diagnosed in our hospital between 2015.9-2024.9 were included and retrospectively analyzed. Among them, 77 PPS patients (49.4%) and 82 PSC patients (46.9%) underwent radical resection, while patients with unresectable diseases received systemic treatment and radiotherapy. Clinical and pathological characteristics were summarized and compared. Survival analysis and multivariable cox regression were also performed using overall survival (OS) data.
resultsThe 5-year survival rates among surgically treated patients were 42.3% for PPS and 32.2% for PSC. Among patients with PPS, the median survival was 3.44 years for those who underwent surgery and 0.52 years for those who did not. In PSC, the median survival was 2.16 years with surgery and 0.96 years without surgery. Perioperative systemic therapy-primarily chemoradiotherapy-did not confer significant survival benefits. In the unresectable population, targeted therapy and immunotherapy may offer prognostic improvement for both PPS and PSC.
conclusionsSurgical resection potentially provides PPS and PSC patients with the opportunity of long-term survival. For unresectable diseases, immunotherapy as well as targeted therapy may contribute to improved survival outcome.
Indexed as
Identifiers
42377697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.